generic semaglutide side effects GLP-1 Semaglutide: Uses, Dosage, Side Effects,

10.1097/00005392-200009010-00024 111 XiangX.WangJ.LuD.XuX

R.Uriu-HareJ

At 52 weeks, the semaglutide group showed a statistically significant reduction in areal bone mineral density at the total hip (estimated treatment difference: -0.020 g/cm, p = 0.001, equating to approximately 2.6% loss) and at the lumbar spine (ETD: -0.018 g/cm, p = 0.007, approximately 2.1% loss)

Subsequently, semaglutide (SEMA), a once-weekly injectable GLP-1 receptor agonist, was launched in 2021.1,3 Structure and mechanism of action Both LIRA and SEMA are subcutaneously administered GLP-1 receptor agonists, sharing 97% and 94% homology, respectively, with the native GLP-1 molecule

Expiration and Storage: Unopened, both sterile water and bacteriostatic water have long shelf lives until their expiration date